The Ministry of Health, Labor and Welfare (MHLW) on January 10 ordered a label revision for Celgene’s multiple myeloma med Revlimid (lenalidomide) to warn of the risk of hepatitis B virus reactivation. In its notification to the Federation of Pharmaceutical…
To read the full story
Related Article
- MHLW Notifies of Package Insert Changes for Iguratimod
February 8, 2017
- PMDA Reviewing Risk of Hep B Virus Reactivation for Revlimid
December 13, 2016
REGULATORY
- Japan to Ease Olanzapine Diabetes Contraindication for Antiemetic Use
July 31, 2026
- Pipe Damage Causes Water Leak at Sawai Plant after Quake: MHLW
July 30, 2026
- MHLW Urges Stable Supply of Drugs after Kumamoto Earthquake
July 30, 2026
- Kumamoto Quake Hits 46 Medical Facilities; No Pharma Damage Yet: MHLW
July 29, 2026
- Japan Shifts Mo-99 Supply Strategy toward Stronger Global Procurement: Panel
July 29, 2026
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…





